Journal Articles on Mesothelioma: 'Cisplatin (Platinol ®)' Category
September 2nd, 2008. Recent advances in the treatment of malignant pleural mesothelioma
Vorinostat, a small molecule inhibitor of HDAC, which targets select members of class I and II HDACs, has shown early evidence of activity and is currently being evaluated in a randomized study for patients who progress with standard therapy for advanced mesothelioma. It is hoped that the HDAC inhibitors and other novel targeted agents will pave the way for improved outcomes for patients with this disease.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Gene Therapy, Pemetrexed (Alimta), Pleural, Pleurectomy/decortication, Radiation, Surgery, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 30th, 2008. Link] Goudar RK. Department of Medicine, Division of Hematology, Medical Oncology and Cellular Therapy, Duke University Medical Center, Durham, NC, USA. Abstract Malignant pleural mesothelioma is a resistant form of lung cancer, and its incidence continues to rise in Europe and Australia. Until recently, chemotherapy had not been shown to be effective in the treatment of this slowly progressive disease. In 2004, the combination of pemetrexed and cisplatin was shown to induce high response rates in MPM. This article reviews the published literature describing the development and testing of this therapeutic combination in mesothelioma, and examines in detail the key phase III clinical trial that led to the approval of pemetrexed by the US FDA. Ongoing research will further define the role of pemetrexed plus cisplatin in the treatment of MPM. Keywords: malignant pleural mesothelioma, mesothelioma, pemetrexed, cisplatin "> Therapeutics and Clinical Risk Management. 2008 Feb;4(1):205-11. [Link] Goudar RK. Department of Medicine, Division of Hematology, Medical Oncology and Cellular Therapy, Duke University Medical Center, Durham, NC, USA. Abstract Malignant pleural mesothelioma is a resistant form of lung cancer, and its incidence continues to rise in Europe and Australia. Until recently, chemotherapy had not been shown to be effective in the treatment of this slowly progressive disease. In 2004, the combination of pemetrexed and cisplatin was shown to induce high response rates in MPM. This article reviews the published literature describing the development and testing of this therapeutic combination in mesothelioma, and examines in detail the key phase III clinical trial that led to the approval of pemetrexed by the US FDA. Ongoing research will further define the role of pemetrexed plus cisplatin in the treatment of MPM. Keywords: malignant pleural mesothelioma, mesothelioma, pemetrexed, cisplatin
This article reviews the published literature describing the development and testing of this therapeutic combination in mesothelioma, and examines in detail the key phase III clinical trial that led to the approval of pemetrexed by the US FDA. Ongoing research will further define the role of pemetrexed plus cisplatin in the treatment of MPM.
July 18th, 2008. Pemetrexed
Addition of folic acid and vitamin B12 significantly reduced the toxicity of pemetrexed, especially hematologic toxicity and gastrointestinal toxicity. Pemetrexed is the expected agent for use in high risk patients, especially elderly or poor performance status patients.
July 3rd, 2008. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program
Conclusion: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaive patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.
June 24th, 2008. Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy
During the follow-up duration of 23 months, 3 patients (18 %) developed distant metastasis and one (6 %) a mediastinal local recurrence. Multimodal therapy of malignant pleural mesothelioma including extrapleural pneumonectomy should only be performed in specialised centres for thoracic surgery where uncomplicated interdisciplinary communication is the rule and which provide the required expertise in patient selection, operative technique and postoperative care.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Pemetrexed (Alimta), Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment: | No Comments »
June 24th, 2008. Chemotherapy of malignant pleural mesothelioma: have we made any progress?
Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients. In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.
June 11th, 2008. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.
June 5th, 2008. Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural, Pleural Biopsy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, thoracoscopy | No Comments »
May 24th, 2008. Effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability
In particular, the two drugs in NCI cell line had a synergistic effect on apoptosis, probably through activation of caspase 8 and caspase 9, while the most evident targets among the cell cycle regulators were cyclin D1 and p21waf1. These results suggest that the association of piroxicam and CDDP specifically triggers cell cycle regulation and apoptosis in different mesothelioma cell lines and may hold promise in the treatment of mesothelioma.
May 20th, 2008. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Interpretation: The addition of chemotherapy to ASC offers no significant benefits in terms of overall survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pleural, Radiation, Survival, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, mitomycin-C | No Comments »
April 25th, 2008. Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients
Conclusion: The Pem/Cis combination provides promising activity and an acceptable safety profile for chemonaive Japanese MPM patients with the same recommend dosage and schedule used in rest of the world.
April 10th, 2008. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Conclusion: Definitive eradication by means of cytoreduction and HIPEC seems a safe and effective therapeutic option for MPM.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 3rd, 2008. The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients
There was no early or late stump insufficiency during the 15-month follow-up. Surgical techniques using muscle flap seems to play a major role in the prevention of bronchus stump insufficiency especially after neo-adjuvant chemotherapy.
Posted in Chemotherapy, Cisplatin (Platinol ®), Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Pleural, Pneumonectomy, Radiation, Surgery, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 1st, 2008. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma
Conclusion: Based on the results of this study, intensive multimodality therapy appears feasible and effective in this group of patients.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment: | No Comments »
March 26th, 2008. Toxin of Staphylococcus aureus overcomes acquired cisplatin-resistance in malignant mesothelioma cells
A low-toxic concentration of alpha-toxin re-sensitized cisplatin P31res cytotoxicity by apoptosis-induced through the mitochondrial pathway without detectable activation of common up-stream apoptosis signaling proteins. The toxin/drug combination should be tested for cisplatin-resistant mesothelioma treatment.
March 25th, 2008. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts
ASO 15999 induced reduction of Bcl-xL is effective in slowing the progression of human mesothelioma cell lines both in vitro and in vivo. More notably, the combination of Bcl-xL ASO and cisplatin extends survival in an orthotopic tumor xenograft model.
March 22nd, 2008. Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
Conclusions: Right EPP and more than 4 units of RBC transfusion are associated with increased risk of major complications. Although patients undergoing induction chemotherapy received more RBC transfusions, induction chemotherapy did not directly impact the risk of major complications.
February 21st, 2008. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
Conclusions: The gemcitabine and vinorelbine combination was moderately active and had an acceptable toxicity profile in pemetrexed-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine | No Comments »
February 13th, 2008. Phase-contrast microscopy studies of early Cisplatin-induced morphological changes of malignant mesothelioma cells and the correspondence to induced apoptosis
Increased membrane protrusions were identified with PCM and SEM, but these were not consistent with the induction of apoptosis. The authors concluded that very early morphological changes can be determined with PCM in MPM, but they did not convincingly correspond to apoptosis induction.
February 2nd, 2008. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice
Conclusions: Pemetrexed/cisplatin demonstrated acceptable cost-effectiveness when compared with cisplatin monotherapy and alternative treatments commonly used in UK clinical practice.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, mitomycin-C | No Comments »
|
|  |
